
Syndax Pharmaceuticals (SNDX) Stock Forecast & Price Target
Syndax Pharmaceuticals (SNDX) Analyst Ratings
Bulls say
Syndax Pharmaceuticals is a promising biopharmaceutical company with a strong pipeline of drugs targeting multiple cancer indications and other diseases. The company's recent positive data in both pre-clinical and clinical studies demonstrate its potential for success in the future. However, investors should still consider the potential risks associated with drug development and competition in the market when evaluating this stock.
Bears say
Syndax Pharmaceuticals is currently facing multiple challenges that could negatively impact its stock. These include the early stages of its product candidates, the competition in the biopharmaceutical industry, and the high financial risk associated with clinical trials and drug development. Additionally, the company faces uncertainty in its ability to successfully develop and commercialize its products, as well as potential resistance mutations and competition from other menin inhibitors. Its current financials also raise concerns, with limited revenue and significant expenses for research and development.
This aggregate rating is based on analysts' research of Syndax Pharmaceuticals and is not a guaranteed prediction by Public.com or investment advice.
Syndax Pharmaceuticals (SNDX) Analyst Forecast & Price Prediction
Start investing in Syndax Pharmaceuticals (SNDX)
Order type
Buy in
Order amount
Est. shares
0 shares